gozetotide
PeptideexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 12, 2021 (NCT05547061)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1- Mol. weight
- 947 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 68-Gallium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3578202 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05547061 | Phase 1/Phase 2 (Phase 2) | Apr 12, 2021 | Cellbion Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellbion Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1